Clinical Report: Tricuspid Regurgitation Thresholds Reassessed
Overview
A study published in JAMA Cardiology identified disease-specific echocardiographic thresholds for tricuspid regurgitation in patients with transthyretin amyloid cardiomyopathy. The study involved 1,124 patients and established new risk thresholds for tricuspid regurgitation measurements.
Background
Tricuspid regurgitation (TR) is a significant clinical condition that can impact patient outcomes, particularly in those with transthyretin amyloid cardiomyopathy. A reassessment of risk thresholds is necessary to improve patient management.
Data Highlights
| Threshold Category | Vena Contracta Width (mm) | Effective Regurgitant Orifice Area (cm²) | Regurgitant Volume (mL) |
|---|---|---|---|
| Intermediate Risk | 3 | 0.15 | 10 |
| High Risk | 5 | 0.25 | 20 |
| Extreme Risk | 8 | 0.50 | 40 |
Key Findings
- The study included 1,124 patients with a median age of 80 years, of whom 23% were female.
- New thresholds for TR were established: 3 mm (intermediate), 5 mm (high), and 8 mm (extreme) for vena contracta width.
- During a median follow-up of 25 months, 29% of patients died and 22% experienced heart failure hospitalization.
- The proposed framework classified 37% of patients as low risk, 34% as intermediate risk, 21% as high risk, and 9% as extreme risk.
- Kaplan-Meier analyses demonstrated stepwise separation in mortality across the risk categories.
- The new framework showed significantly greater discrimination than existing guidelines from 24 months onward in the validation cohort.
Clinical Implications
Clinicians should consider the newly established thresholds when evaluating TR severity and associated risks in patients with transthyretin amyloid cardiomyopathy.
Conclusion
The study highlights the need for updated risk thresholds for tricuspid regurgitation in transthyretin amyloid cardiomyopathy.
Related Resources & Content
- Hauptmann L, et al., JAMA Cardiology, 2023 -- Tricuspid regurgitation thresholds reassessed
- Frontiers in Cardiovascular Medicine — A comparison of the severity of tricuspid valve regurgitation between echocardiographic and cardiac magnetic resonance criteria in adults with congenital heart disease
- Pediatric Cardiology — Tricuspid Regurgitation and Impact of Surgical Valve Intervention in the Single Ventricle Reconstruction Trial
- MDSpire News — Study Evaluates TR Risk Scores' Predictive Value
- Clinical Research in Cardiology — Impact of Previous Cardiac Surgery on Outcomes After Tricuspid Valve Transcatheter Edge-to-Edge Repair: Insights from EuroTR
- A comparison of the severity of tricuspid valve regurgitation between echocardiographic and cardiac magnetic resonance criteria in adults with congenital heart disease
- Tricuspid Regurgitation and Impact of Surgical Valve Intervention in the Single Ventricle Reconstruction Trial
- Study Evaluates TR Risk Scores' Predictive Value
- 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) - EACTS
- Transcatheter Repair for Patients with Tricuspid Regurgitation | New England Journal of Medicine
- 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee | JACC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
